Related Experiment Video
Updated: Apr 4, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells
Ting Shuang1, Min Wang1, Cong Shi1
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Abstract:
MiR-134 has been reported to have a role in the development and progression of various cancers. In this study, we found that miR-134 expression was significantly decreased in chemo-resistant serous epithelial ovarian cancer (EOC) patients. Over-expression of miR-134 enhanced the sensitivity of SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis. Further, Pak2 was identified as a direct target of miR-134, and Pak2-specific siRNA increased cell inhibition rate and promoted paclitaxal-induced apoptosis. By regulating Pak2 expression, miR-134 could mediate Bad phosphorylation at Ser112 and Ser136, which affected cell survival and apoptosis. In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance.
Related Concept Videos
MicroRNAs
MicroRNAs
Drugs that Stabilize Microtubules
Treatment Resistant Cancers
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

